Keytruda

News

AZ/Daiichi partner with Merck on first-line lung cancer tria...

The dominance of Merck & Co's Keytruda in the treatment of previously-untreated non-small cell lung cancer (NSCLC) means it will be hard to dislodge – so AstraZeneca and Daiichi Sankyo

News

Merck gets EU approval for Keytruda in triple-negative breas...

Merck & Co has claimed EU approval for Keytruda in triple-negative breast cancer (TNBC), a particularly hard-to-treat form of the disease.

News

BMS strikes back against Merck in EU oesophageal cancer mark...

Merck & Co's Keytruda become the first cancer immunotherapy to be approved as a first-line oesophageal cancer treatment in the EU earlier this year, but will now face competition from B

News

Roche scores adjuvant lung cancer approval for Tecentriq

Roche has claimed an earlier-than-expected FDA approval for its checkpoint inhibitor Tecentriq in non-small cell lung cancer (NSCLC), giving the drug a lead in early-stage cases that can be

News

Keytruda's liver cancer approval secured by new study

Merck & Co's FDA approval for Keytruda in advanced liver cancer looks secure, after an Asian clinical trial found that the cancer immunotherapy improved survival in these patients.

News

ESMO21: Libtayo extends survival in first-line NSCLC, challe...

There's no shortage of cancer immunotherapies trying to knock Merck & Co's Keytruda off the top of the tree in previously-untreated non-small cell lung cancer (NSCLC).

AZ/Daiichi partner with Merck on first-line lung cancer tria...

Merck gets EU approval for Keytruda in triple-negative breas...

BMS strikes back against Merck in EU oesophageal cancer mark...

Roche scores adjuvant lung cancer approval for Tecentriq

Keytruda's liver cancer approval secured by new study

ESMO21: Libtayo extends survival in first-line NSCLC, challe...

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

Keytruda

Editor's Picks